Hertzel Gerstein talks with The Lancet Diabetes & Endocrinology about how dulaglutide might reduce the incidence of moderate or severe erectile dysfunction in men with type 2 diabetes. Read the full article:  https://www.thelancet.com/journals/landia/article/PIIS2213-8587(21)00115-7/fulltext

Hertzel Gerstein talks with The Lancet Diabetes & Endocrinology about how dulaglutide might reduce the incidence of moderate or severe erectile dysfunction in men with type 2 diabetes. Read the full article: https://www.thelancet.com/journals/landia/article/PIIS2213-8587(21)00115-7/fulltext

Hertzel Gerstein talks with The Lancet Diabetes &amp; Endocrinology about how dulaglutide might reduce the incidence of moderate or severe erectile dysfunction in men with type 2 diabetes. Read the full article:&nbsp; https://www.thelancet.com/journals/landia/article/PIIS2213-8587(21)00115-7/fulltext

Hertzel Gerstein on dulaglutide, erectile dysfunction, and T2D

Our Editors and and the journal’s authors explore their research and its impact on people’s health, health care, and health policy in this regular podcast.

Share Hertzel Gerstein on dulaglutide, erectile dysfunction, and T2D

Sign up to save your podcasts

Hertzel Gerstein on dulaglutide, erectile dysfunction, and T2D

Hertzel Gerstein on dulaglutide, erectile dysfunction, and T2D